Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

Gilead is also evaluating investigational regimens for HIV with once-daily, once-weekly and twice-yearly dosing frequencies. In August 2024, the FDA granted accelerated approval to seladelpar for ...

Exelixis, Inc. today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis ...

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, today announced it has been named to G2's 2025 Best ...

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...

Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...